赵树立

发布者：陈洁洋发布时间：2019-09-30浏览次数：3639


赵树立 中国药科大学专业学位药学（临床药学）硕士生导师

南京市第一医院, 临床研究中心

南京市秦淮区长乐路68号

E-mail: shulizhao79@163.com

联系电话：025-52887003


  1. 社会兼职

博士、副研究员，江苏省毒理学会理事、江苏省临床免疫检验专业委员会常务委员、江苏省免疫与代谢专业委员会常务委员、江苏省转化医学专业委员会常务委员。入选江苏省“六大人才高峰”高层次人才和江苏省青年医学人才培养计划。

  1. 研究方向：

主要从事于肿瘤微环境成分分析及其介导的免疫逃逸机制和天然免疫介导的肿瘤免疫治疗技术开发。本课题组经费充足，热忱欢迎有志于从事肿瘤免疫治疗新技术研发的同学加入，为我国临床肿瘤治疗技术研究奉献青春和力量。

  1. 主持项目：

国家自然科学基金3项（在研1项）、江苏省重点研发计划（临床前沿技术）1项（在研）、南京市医学科研发展重点项目3项等（在研1项）。

  1. 近5年部分成果（*通讯作者）：

  1.  Rong D, Lu C, Zhang B, Fu K, Zhao S*, Tang W*, Cao H*. CircPSMC3 suppresses the proliferation and metastasis of gastric cancer by acting as a competitive endogenous RNA through sponging miR-296-5p. Mol Cancer. 2019 Feb 18;18(1):25.  

  2.  Xuefeng Zhang, Jing Wang, Jing Lu, Rongrong Li and Shuli Zhao*. Immunogenicity of adenovirus-vector vaccine targeting hepatitis B virus: non-clinical safety assessment in non-human primates. Virology Journal (2018) 15:111.  

  3.  Jiaojiao Zhao, Yaxian Xue, Yuchen Pan, Anran Yao, Guoqun Wang, Dan Li, Tingting Wang, Shuli Zhao* and Yayi Hou*. Toll‐like receptor 3 agonist poly I:C reinforces the potency of cytotoxic chemotherapy via the TLR3‐UNC93B1‐IFN‐β signaling axis in paclitaxel‐resistant colon cancer. J Cell Physiol. 2019 May;234(5):7051-7061.

  4.  Jiaojiao Zhao, Zhengkui Zhang, Yaxian Xue, Guoqun Wang, Yuan Cheng, Yuchen Pan, Shuli Zhao* and Yayi Hou. Anti-tumor macrophages activated by ferumoxytol combined or surface-functionalized with the TLR3 agonist poly(I:C) promote melanoma regression. Theranostics 2018, Vol. 8, Issue 22.  

  5.  Li Y#, Yang Y#, Xiong A, Wu X, Xie J, Han S, Zhao S*. Comparative Gene Expression Analysis of Lymphocytes Treated with Exosomes Derived from Ovarian Cancer and Ovarian Cysts. Front Immunol. 2017 Jun 1;8:607.  

  6.  Zhao J#, Pan Y, Li X, Zhang X, Xue Y, Wang T, Zhao S*, Hou Y*. Dihydroartemisinin and Curcumin Synergistically Induce Apoptosis in SKOV3 Cells Via Upregulation of MiR-124 Targeting Midkine. Cell Physiol Biochem. 2017;43(2):589-601.

  7.  Zhang D#, Ding L, Li Y, Ren J, Shi G, Wang Y,Zhao S*, Ni Y*, Hou Y*. Midkine derived from cancer-associated fibroblasts promotes cisplatin-resistance via up-regulation of the expression of lncRNA ANRIL in tumour cells. Sci Rep. 2017 Nov 24;7(1):16231.  

  8. Shuli Zhao#, Zhengtao Chu, Victor M. Blanco,Yunzhong Nie,Yayi Hou, Xiaoyang Qi. SapC–DOPS Nanovesicles as Targeted Therapy for Lung Cancer. Mol Cancer Ther; 2015, 14(2); 491–8.  

  9.  Xiaoqing Wu, Xiaogai Zhi, Minghua Ji, Qingling Wang, Yujuan Li, Jingyan Xie* and Shuli Zhao*. Midkine as a potential diagnostic marker in epithelial ovarian cancer for cisplatin/paclitaxel combination clinical therapy. American Journal of Cancer Research. 2015,15;5(2):629-38.  

  10.  Ren J, Nie Y, Lv M, Shen S, Tang R, Xu Y, Hou Y, Zhao S*, Wang T*. Estrogen upregulates MICA/B expression in human non-small cell lung cancer through the regulation of ADAM17. Cell Mol Immunol. 2015 Nov;12(6):768-76.  

  11.  Xie J, Liu M, Li Y, Nie Y, Mi Q, Zhao S*. Ovarian tumor-associated microRNA-20a decreases natural killer cell cytotoxicity by downregulating MICA/B expression. Cell Mol Immunol. 2014 Sep;11(5):495-502.  

  12. Zhao SL#, Zhang YJ#, Li MH, Zhang XL, Chen SL. Mesenchymal stem cells with overexpression of midkine enhance cell survival and attenuate cardiac dysfunction in a rat model of myocardial infarction.Stem Cell Res Ther. 2014 Mar 17;5(2):37.  

  13. 授权专利：获得美国发明专利1项，中国发明专利4项

  14. 编著：《生物等效性试验实用指南》，江苏凤凰科学技术出版社，2018年（编委）